IDEAYA Biosciences (IDYA) CAO exercises options, sells 9,550 pre-planned shares

Rhea-AI Filing Summary

IDEAYA Biosciences’ Chief Accounting Officer Andres Ruiz Briseno exercised stock options and sold shares in a pre-planned transaction. On July 7, 2026, he exercised 9,550 stock options at $12.86 per share to acquire common stock, then sold 9,550 common shares in open-market trades at a weighted average price of about $40.01 per share. The sale was executed under his Rule 10b5-1 trading plan adopted on December 19, 2025. Following these transactions, he directly owned 26,466 shares of IDEAYA Biosciences common stock.

Insider Trade Summary 10b5-1

Net Seller: 9,550 shares ($382,131)

Net Sell 3 txns

Insider Ruiz Briseno Andres

Role Chief Accounting Officer

Sold 9,550 shs ($382K)

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy)	9,550	$0.00	--
Exercise	Common Stock	9,550	$12.86	$123K
Sale	Common Stock	9,550	$40.0137	$382K

Holdings After Transaction: Stock Option (Right to Buy) — 19,200 shares (Direct); Common Stock — 36,016 shares (Direct)

Footnotes (1)

1. The transaction reported herein was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on December 19, 2025. This transaction was executed in multiple trades in prices ranging from $40.00 to $40.10, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. 100% of the shares subject to the option is fully vested and exercisable.

Key Figures

Shares sold: 9,550 shares Sale price: $40.0137 per share Options exercised: 9,550 shares +2 more

5 metrics

Shares sold 9,550 shares Common stock sold in open-market transaction on July 7, 2026

Sale price $40.0137 per share Weighted average sale price for 9,550 common shares

Options exercised 9,550 shares Stock options exercised into common stock on July 7, 2026

Exercise price $12.86 per share Exercise price of stock options converted into common stock

Shares owned after 26,466 shares Direct common stock holdings after transactions

Key Terms

Rule 10b5-1 trading plan, weighted average sale price, Stock Option (Right to Buy), fully vested and exercisable

4 terms

Rule 10b5-1 trading plan regulatory

"The transaction reported herein was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average sale price financial

"The price reported in Column 4 above reflects the weighted average sale price"

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

fully vested and exercisable financial

"100% of the shares subject to the option is fully vested and exercisable"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 07/09/2026 - 04:57 PM Accepted by SEC EDGAR 07/09/2026 - 04:56 PM Learn about SEC filing dates

FAQ

What did IDEAYA Biosciences (IDYA) executive Andres Ruiz Briseno do in this Form 4?

Andres Ruiz Briseno, Chief Accounting Officer of IDEAYA Biosciences, exercised 9,550 stock options at $12.86 and sold 9,550 common shares in open-market trades around $40.01 per share, all under a pre-established Rule 10b5-1 trading plan.

How many IDEAYA Biosciences (IDYA) shares did the CAO sell and at what price?

He sold 9,550 IDEAYA Biosciences common shares in open-market transactions. The filing reports a weighted average sale price of approximately $40.0137 per share, with individual trade prices ranging from $40.00 to $40.10 during the transaction date.

What stock options did the IDEAYA Biosciences (IDYA) CAO exercise in this filing?

He exercised 9,550 stock options, each giving the right to buy one IDEAYA Biosciences common share at an exercise price of $12.86 per share. The filing notes that 100% of the shares subject to this option were fully vested and exercisable.

Was the IDEAYA Biosciences (IDYA) insider sale under a Rule 10b5-1 plan?

Yes. The filing states the transaction was effected pursuant to Andres Ruiz Briseno’s Rule 10b5-1 trading plan, adopted on December 19, 2025, indicating the sale was pre-planned rather than a discretionary, opportunistic trade based on short-term market movements.

How many IDEAYA Biosciences (IDYA) shares does the CAO own after these transactions?

After exercising options and selling shares, Andres Ruiz Briseno directly holds 26,466 shares of IDEAYA Biosciences common stock. This figure, reported in the Form 4, reflects his remaining direct equity position following the July 7, 2026 transactions.

What does the price range disclosure mean in the IDEAYA Biosciences (IDYA) Form 4?

The filing explains that sales occurred in multiple trades between $40.00 and $40.10 per share. The reported $40.0137 is a weighted average. The insider undertakes to provide detailed trade-by-trade information to regulators or shareholders upon request.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ruiz Briseno Andres

(Last) (First) (Middle)

C/O IDEAYA BIOSCIENCES, INC.

5000 SHORELINE COURT, SUITE 300

(Street)

SOUTH SAN FRANCISCO CALIFORNIA 94080

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
IDEAYA Biosciences, Inc. [ IDYA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Accounting Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/07/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/07/2026		M		9,550	A	$12.86	36,016	D
Common Stock	07/07/2026		S(1)		9,550	D	$40.0137(2)	26,466	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$12.86	07/07/2026		M			9,550	(3)	03/01/2032	Common Stock	9,550	$0	19,200	D

Explanation of Responses:

1. The transaction reported herein was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on December 19, 2025.

2. This transaction was executed in multiple trades in prices ranging from $40.00 to $40.10, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

3. 100% of the shares subject to the option is fully vested and exercisable.

	/s/ Andres Ruiz Briseno	07/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)